These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 7160291)

  • 1. [Monitoring heparin for anticoagulation during cardiopulmonary bypass].
    Li LH
    Zhonghua Xin Xue Guan Bing Za Zhi; 1982 Dec; 10(4):251-5. PubMed ID: 7160291
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of blood loss and heparin rebound following cardiopulmonary bypass.
    Pifarre R; Sullivan HJ; Montoya A; Bakhos M; Grieco J; Foy BK; Blakeman B
    Semin Thromb Hemost; 1989 Apr; 15(2):173-7. PubMed ID: 2787532
    [No Abstract]   [Full Text] [Related]  

  • 3. [Heparin monitoring during cardiopulmonary bypass in congenital heart surgery].
    Isomatsu Y; Imai Y; Seo K; Terada M; Aoki M; Shin'oka T
    Kyobu Geka; 2000 Nov; 53(12):1001-4. PubMed ID: 11079303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
    Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR
    J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin monitoring during cardiopulmonary bypass.
    Saleem A; Shenaq SS; Yawn DH; Harshberger K; Diemunsch P; Mohindra P
    Ann Clin Lab Sci; 1984; 14(6):474-9. PubMed ID: 6508227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring of blood coagulation in open heart surgery. II. Use of individualized dosages of heparin and protamine controlled by activated coagulation times.
    Dercksen SJ; Linssen GH
    Acta Anaesthesiol Belg; 1980; 31(2):121-8. PubMed ID: 7468138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass.
    Slight RD; Buell R; Nzewi OC; McClelland DB; Mankad PS
    J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):47-52. PubMed ID: 18249330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring of blood coagulation in open heart surgery. I. Effects of conventional dosages of heparin and protamine.
    Dercksen SJ; Linssen GH
    Acta Anaesthesiol Belg; 1980; 31(2):113-9. PubMed ID: 7468137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass.
    Esposito RA; Culliford AT; Colvin SB; Thomas SJ; Lackner H; Spencer FC
    J Thorac Cardiovasc Surg; 1983 Feb; 85(2):174-85. PubMed ID: 6823136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of postoperative heparin rebound following cardiopulmonary bypass.
    Pifarré R; Babka R; Sullivan HJ; Montoya A; Bakhos M; El-Etr A
    J Thorac Cardiovasc Surg; 1981 Mar; 81(3):378-81. PubMed ID: 7464201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage.
    Bull BS; Huse WM; Brauer FS; Korpman RA
    J Thorac Cardiovasc Surg; 1975 May; 69(5):685-9. PubMed ID: 1127967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A clinical evaluation of the Hepcon/HMS: a new device of monitoring hemostasis management during cardiopulmonary bypass].
    Yamanishi H; Watanabe S; Hayashi K; Tomioka H; Minami M; Nozaki Y; Aoki T; Kawai Y; Kishino K; Ohta S
    Kyobu Geka; 1997 Jun; 50(6):459-62. PubMed ID: 9185440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aprotinin and heparin monitoring during cardiopulmonary bypass.
    Hunt BJ; Segal H; Yacoub M
    Circulation; 1992 Nov; 86(5 Suppl):II410-2. PubMed ID: 1385011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two protocols for heparin neutralization by protamine after cardiopulmonary bypass.
    Arén C; Feddersen K; Rådegran K
    J Thorac Cardiovasc Surg; 1987 Oct; 94(4):539-41. PubMed ID: 3309479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated clotting time for control of anticoagulation during surgery.
    Lefemine AA; Lewis M
    Am Surg; 1985 May; 51(5):274-8. PubMed ID: 3994170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin resistance during cardiopulmonary bypass. The role of heparin pretreatment.
    Esposito RA; Culliford AT; Colvin SB; Thomas SJ; Lackner H; Spencer FC
    J Thorac Cardiovasc Surg; 1983 Mar; 85(3):346-53. PubMed ID: 6827843
    [No Abstract]   [Full Text] [Related]  

  • 17. Activated clotting time monitoring of intraoperative heparinization: our experience and comparison of two techniques.
    Mabry CD; Thompson BW; Read RC; Campbell GS
    Surgery; 1981 Nov; 90(5):889-95. PubMed ID: 7302842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass surgery.
    Babka R; Colby C; El-Etr A; Pifarré R
    J Thorac Cardiovasc Surg; 1977 May; 73(5):780-2. PubMed ID: 850438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protamine dosing--the quandary continues.
    Hall RI
    Can J Anaesth; 1998 Jan; 45(1):1-5. PubMed ID: 9466018
    [No Abstract]   [Full Text] [Related]  

  • 20. Low activated coagulation time during cardiopulmonary bypass does not increase postoperative bleeding.
    Metz S; Keats AS
    Ann Thorac Surg; 1990 Mar; 49(3):440-4. PubMed ID: 2310251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.